Institutional shares held 96.8 Million
36.9K calls
83K puts
Total value of holdings $266M
$101K calls
$228K puts
Market Cap $131M
47,617,700 Shares Out.
Institutional ownership 203.32%
# of Institutions 153


Latest Institutional Activity in ANNX

Top Purchases

Q2 2025
Park Avenue Securities LLC Shares Held: 113K ($311K)
Q1 2025
Ameriprise Financial Inc Shares Held: 3.99M ($11M)
Q1 2025
Logos Global Management LP Shares Held: 4M ($11M)
Q1 2025
Tfg Asset Management Gp LTD Shares Held: 2.65M ($7.29M)
Q1 2025
Sio Capital Management, LLC Shares Held: 3.4M ($9.34M)

Top Sells

Q1 2025
Point72 Asset Management, L.P. Shares Held: 45.7K ($126K)
Q1 2025
State Street Corp Shares Held: 2.04M ($5.61M)
Q1 2025
Price T Rowe Associates Inc Shares Held: 525K ($1.44M)
Q1 2025
Woodline Partners LP Shares Held: 2.11M ($5.82M)
Q1 2025
Goldman Sachs Group Inc Shares Held: 842K ($2.31M)

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.


Insider Transactions at ANNX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
175K Shares
From 3 Insiders
Exercise of conversion of derivative security 158K shares
Open market or private purchase 16.9K shares
Sell / Disposition
72.4K Shares
From 6 Insiders
Open market or private sale 72.4K shares

Track Institutional and Insider Activities on ANNX

Follow Annexon, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ANNX shares.

Notify only if

Insider Trading

Get notified when an Annexon, Inc. insider buys or sells ANNX shares.

Notify only if

News

Receive news related to Annexon, Inc.

Track Activities on ANNX